Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): A randomised controlled trial

Thumbnail Image
File version

Version of Record (VoR)

Schlapbach, LJ
Horton, SB
Long, DA
Beca, J
Erickson, S
Festa, M
D'Udekem, Y
Alphonso, N
Winlaw, D
Johnson, K
Delzoppo, C
Van Loon, K
Gannon, B
Fooken, J
Blumenthal, A
Young, P
Jones, M
Butt, W
Schibler, A
Griffith University Author(s)
Primary Supervisor
Other Supervisors
File type(s)

Introduction: Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol.

Methods and analysis: The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants <2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age (<6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery.

Ethics and dissemination: The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal.

Trial registration number: ACTRN12617000821392

Journal Title

BMJ Open

Conference Title
Book Title




Thesis Type
Degree Program
Publisher link
Patent number
Grant identifier(s)
Rights Statement
Rights Statement

© The Author(s). Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.

Item Access Status
Access the data
Related item(s)

Clinical sciences

Health services and systems

Public health

Other health sciences

Persistent link to this record

Schlapbach, LJ; Horton, SB; Long, DA; Beca, J; Erickson, S; Festa, M; D'Udekem, Y; Alphonso, N; Winlaw, D; Johnson, K; Delzoppo, C; Van Loon, K; Gannon, B; Fooken, J; Blumenthal, A; Young, P; Jones, M; Butt, W; Schibler, A, Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): A randomised controlled trial, BMJ Open, 2019, 9 (8), pp. e026664:1-e026664:8